StatOrigin open statistical archive
Industries Indicators Regions Rankings Compare Sources

Sanofi

40 data points extracted from 2 publications by this organisation.

Cite & reuse Official site Get this data as JSON
Data points
40
Documents
2
Indicators
32
Regions
4
Publisher type
Company

Bibliography

Documents used

Every publication we have taken a number from, with the date we read it and the link status at that time.

Document Type Published Retrieved Link Data points
Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines Licence: See source Press release 14 Sep 2026 15 Sep 2026 Reachable 4
Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded Licence: See source Press release 30 Jul 2026 15 Sep 2026 Reachable 36

Every figure

Data points

Every figure taken from this organisation, grouped by indicator.

40 data points across 32 indicators.
IndicatorRegionPeriodValueTypeFull record
Annual net sales growth guidance at constant exchange ratesGlobal202610%forecast →
Business earnings per shareGlobalQ2 20262.09 EURactual →
Business earnings per share growthGlobalQ2 202631.4%actual →
Business EPS growth at constant exchange ratesGlobalQ2 202633.3%actual →
Dupixent salesGlobalQ2 20265.2 billion EURactual →
Dupixent sales (annual)Global203025 billion EURforecast →
Dupixent sales growthGlobalQ2 202637.6%actual →
Free cash flowGlobalQ2 20262,670 million EURactual →
Free cash flowGlobalQ1 20263,724 million EURactual →
Free cash flow (half year)Globalas of 30 Jun 20263,724 million EURactual →
Free cash flow growthGlobalQ2 202686.8%actual →
Free cash flow growthGlobalQ1 202651.5%actual →
Free cash flow growth (half year)Globalas of 30 Jun 202651.5%actual →
IFRS earnings per shareGlobalQ2 20260.29 EURactual →
IFRS earnings per shareGlobalQ1 20261.63 EURactual →
IFRS earnings per share (half year)Globalas of 30 Jun 20261.63 EURactual →
IFRS earnings per share growthGlobalQ2 2026-91%actual →
IFRS earnings per share growthGlobalQ1 2026-65.6%actual →
IFRS earnings per share growth (half year)Globalas of 30 Jun 2026-65.6%actual →
IFRS net incomeGlobalQ2 2026343 million EURactual →
IFRS net incomeGlobalQ1 20261,957 million EURactual →
IFRS net income (half year)Globalas of 30 Jun 20261,957 million EURactual →
IFRS net income growthGlobalQ2 2026-91.3%actual →
IFRS net income growthGlobalQ1 2026-66.3%actual →
IFRS net income growth (half year)Globalas of 30 Jun 2026-66.3%actual →
Pharmaceutical launches salesGlobalQ2 20261.3 billion EURactual →
Pharmaceutical launches sales (annual)Global203010 billion EURforecast →
Pharmaceutical launches sales growthGlobalQ2 202648.3%actual →
Pharmaceutical manufacturing employmentFranceas of 14 Sep 202665estimate →
Pharmaceutical manufacturing employmentHungaryas of 14 Sep 2026400estimate →
Pharmaceutical manufacturing employmentSingaporeas of 14 Sep 2026100estimate →
Pharmaceutical marketing authorizationsGlobalas of 14 Sep 20263,440actual →
Research and development expensesGlobalQ2 20262.2 billion EURactual →
Research and development expenses growthGlobalQ2 202617.9%actual →
Sales growth at constant exchange ratesGlobalQ2 202617.8%actual →
Sales growth at constant exchange rates (annual)Global202610%forecast →
Selling and general expensesGlobalQ2 20262.5 billion EURactual →
Selling and general expenses growthGlobalQ2 20269%actual →
Vaccines salesGlobalQ2 20261.1 billion EURactual →
Vaccines sales growthGlobalQ2 2026-4.7%actual →

Cite & reuse

Cite this page

Data on this page is published under CC BY 4.0. Credit Sanofi as the original publisher; each record page carries its own citation.

Sanofi. Retrieved from StatOrigin: https://statorigin.org/sources/sanofi

This organisation as JSON

Keep exploring

Related

Industries using this source

Go further

Last verified 17 September 2026. Link status is rechecked weekly.